News

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...
Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...
Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...
If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...
Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...
The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...
Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of ...